NCT02280655

Brief Summary

Transfusion of red blood cells is often used in critically ill patients with low red blood cell counts to prevent disease progression and death. Recent studies suggest that the use of "aged" versus "fresh" red blood cells are associated with worse clinical outcomes. There is evidence that red blood cells work with the cells lining our blood vessels to produce a variety of substances that normally cause arteries to relax and increase blood supply. Two of these substances are called nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF). The investigators are trying to determine the nature of these substances in human beings when they are transfused "aged" versus "fresh" red blood cells. The purpose of the study is to test the effects of transfusing "aged" versus "fresh" red blood cells in volunteers with traditional cardiovascular risk factors (high blood pressure, diabetes, high cholesterol, and tobacco use) on 1) the degree of relaxation in the arteries and subsequent changes in blood flow, 2) blood levels of oxidant molecules, 3) inflammation, and 4) stem cells. A similar study with healthy volunteers are further described in NCT00838331.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
43

participants targeted

Target at below P25 for phase_2 cardiovascular-diseases

Timeline
Completed

Started Apr 2009

Typical duration for phase_2 cardiovascular-diseases

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2009

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2012

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2013

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

October 29, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 31, 2014

Completed
1 month until next milestone

Results Posted

Study results publicly available

December 4, 2014

Completed
Last Updated

April 11, 2016

Status Verified

April 1, 2016

Enrollment Period

3.6 years

First QC Date

October 29, 2014

Results QC Date

November 4, 2014

Last Update Submit

April 7, 2016

Conditions

Keywords

Blood Transfusions

Outcome Measures

Primary Outcomes (2)

  • Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at Baseline

    Ultrasonography of the brachial artery performed at the bedside using a high-resolution 10-megahertz (MHz) ultrasound transducer before and after suprasystolic inflation of a blood pressure cuff for 5 minutes in the ipsilateral upper arm. Brachial artery FMD was calculated as (hyperemic diameter - baseline diameter)/baseline diameter × 100.

    Baseline

  • Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at 24 Hours After Transfusion

    Ultrasonography of the brachial artery performed at the bedside using a high-resolution 10-megahertz (MHz) ultrasound transducer before and after suprasystolic inflation of a blood pressure cuff for 5 minutes in the ipsilateral upper arm. Brachial artery FMD was calculated as (hyperemic diameter -24 hour diameter)/24 hour diameter × 100.

    24 hours after transfusion

Study Arms (2)

Storage-aged red blood cells (saRBCs)

ACTIVE COMPARATOR

Subjects with cardiovascular disease (CVD) received a transfusion with older stored red blood cells (RBCs) units. The units had been stored for greater than 21 days.

Biological: Storage-aged red blood cells (saRBCs) units

Fresh red blood cells (RBCs)

ACTIVE COMPARATOR

Subjects with cardiovascular disease (CVD) received a transfusion with fresh red blood cells (RBCs) units. The units had been stored for less than 14 days.

Biological: Fresh red blood cells units

Interventions

Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)

Storage-aged red blood cells (saRBCs)

Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)

Fresh red blood cells (RBCs)

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Inpatient or outpatient at Emory University Hospital who's physicians have ordered a transfusion of packed red blood cells (pRBCs) of 1 or more units
  • Cardiovascular risk factors (hypercholesterolemia, diabetes, hypertension, and tobacco smoking) or known cardiovascular disease) will be carefully documented for each subject
  • Cardiac risk factors are defined as follows:
  • Hypercholesterolemia: Defined as serum low density lipoprotein cholesterol \> 140 mg/dL if not currently on lipid-lowering therapy or \> 100 mg/dL if on lipid-lowering therapy
  • Diabetes: Defined as having fasting blood glucose sample of \> 126 mg/dL or a hemoglobin A1c of \> 7% or being treated with diabetes medications such as oral hypoglycemic agents, insulin sensitizing agents, or subcutaneous insulin
  • Smoking: active tobacco use, 20 cigarettes per day for the past year
  • Hypertension: Blood pressure of \> 140/90 or currently on anti-hypertensive medications
  • Cardiovascular disease: known coronary artery disease by angiogram or documented myocardial infarction

You may not qualify if:

  • Pregnancy
  • Previous transfusion within one week.
  • Inability to give informed consent
  • On oral or IV nitrate therapy
  • On vasopressor agents
  • Active illicit drug use

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Emory University

Atlanta, Georgia, 30322, United States

Location

MeSH Terms

Conditions

Cardiovascular Diseases

Limitations and Caveats

Only patients receiving routine transfusions were included in the study, thus excluding critically ill/actively bleeding patients requiring emergent transfusions.

Results Point of Contact

Title
Dr. John D. Roback
Organization
Emory University

Study Officials

  • John Roback, MD, PhD

    Emory University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

October 29, 2014

First Posted

October 31, 2014

Study Start

April 1, 2009

Primary Completion

November 1, 2012

Study Completion

October 1, 2013

Last Updated

April 11, 2016

Results First Posted

December 4, 2014

Record last verified: 2016-04

Locations